Press coverage about TG Therapeutics (NASDAQ:TGTX) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TG Therapeutics earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.010604874939 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

TG Therapeutics (NASDAQ TGTX) opened at 12.20 on Thursday. The company’s market cap is $760.18 million. The firm has a 50-day moving average of $11.09 and a 200-day moving average of $10.47. TG Therapeutics has a 52 week low of $4.10 and a 52 week high of $15.35.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.01. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 68,806.59% and a negative return on equity of 154.02%. Equities analysts forecast that TG Therapeutics will post ($1.84) earnings per share for the current year.

Several research firms recently weighed in on TGTX. Jefferies Group LLC reissued a “buy” rating and set a $23.00 price objective on shares of TG Therapeutics in a research note on Monday, June 5th. BidaskClub raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. ValuEngine raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Zacks Investment Research lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 16th. Finally, FBR & Co reaffirmed a “buy” rating on shares of TG Therapeutics in a research note on Thursday, May 18th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. TG Therapeutics has a consensus rating of “Buy” and a consensus price target of $25.40.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at

In related news, CFO Sean A. Power sold 59,976 shares of the business’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $11.09, for a total transaction of $665,133.84. Following the transaction, the chief financial officer now directly owns 477,464 shares in the company, valued at $5,295,075.76. The sale was disclosed in a filing with the SEC, which is available through this link. 16.70% of the stock is currently owned by insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Insider Buying and Selling by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.